-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Molecular MRD in a Phase 1 Study of Maintenance Azacitidine/Venetoclax after RIC-Ven Allogeneic HSCT in High Risk Myeloid Malignancies

Program: Special-Interest Sessions
Session: Promoting Minorities in Hematology (PMH) Oral Presentations: Room I (for in-person participants)
Saturday, December 9, 2023, 6:30 PM-8:00 PM

H. Moses Murdock, MD

Dana-Farber Cancer Institute, Boston, MA

Disclosures: No relevant conflicts of interest to declare.